高通14亿美元收购苹果手机晶片部门前高层成立的晶片初创Nuvia
美国智能手机晶片巨擘高通(QCOM.US)宣布,以14亿美元收购晶片初创Nuvia,以推动公司在智能手机、手提电脑及汽车的晶片业务,并试图在晶片业界重建领导地位,与苹果及英特尔等竞争。
Nuvia由3名苹果半导体分支前高层创办,该分支负责iPhone手机晶片。Nuvia曾为客户负责中央处理器晶片核心设计,有关设计被用作伺服器晶片上。高通过去数年已向南韩三星电子及微软供应个人电脑晶片,微软(MSFT.US)发声明指欢迎有关收购,并指将有广大的机会让客户进入微软的视窗生态系统。
高通此举有助减少对Arm的依赖,且使用更多自订核心设计可减少向Arm支付的授权成本,甚至未来可更轻易地转用其他晶片框架。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.